Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. Co.'s portfolio includes: Vadadustat, which is an investigational, oral hypoxia-inducible factor prolyl hydroxylase inhibitor for two indications, anemia due to chronic kidney disease (CKD), in adult patients on dialysis, and anemia due to CKD in adult patients not on dialysis; and Auryxia® (ferric citrate), for the control of serum phosphorus levels in adult patients on dialysis, or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients not on dialysis, or the IDA Indication; The AKBA stock yearly return is shown above.
The yearly return on the AKBA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AKBA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|